ThermoGenesis (NASDAQ:THMO) Shares Down 14%

Share on StockTwits

ThermoGenesis Holdings, Inc. (NASDAQ:THMO)’s stock price was down 14% on Tuesday . The stock traded as low as $2.81 and last traded at $3.02. Approximately 787,233 shares traded hands during mid-day trading, a decline of 61% from the average daily volume of 1,996,201 shares. The stock had previously closed at $3.51.

Several analysts recently weighed in on THMO shares. Zacks Investment Research cut shares of ThermoGenesis from a “hold” rating to a “sell” rating in a report on Saturday. HC Wainwright reduced their target price on shares of ThermoGenesis from $9.50 to $8.50 and set a “buy” rating on the stock in a report on Friday, November 13th.

The company has a quick ratio of 1.21, a current ratio of 2.23 and a debt-to-equity ratio of 1.80. The business’s fifty day simple moving average is $3.01 and its two-hundred day simple moving average is $2.94. The company has a market cap of $23.54 million, a price-to-earnings ratio of -0.67 and a beta of 3.11.

An institutional investor recently bought a new position in ThermoGenesis stock. Diametric Capital LP acquired a new position in shares of ThermoGenesis Holdings, Inc. (NASDAQ:THMO) during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 38,257 shares of the company’s stock, valued at approximately $111,000. Diametric Capital LP owned approximately 0.57% of ThermoGenesis at the end of the most recent quarter. 3.13% of the stock is owned by institutional investors and hedge funds.

ThermoGenesis Company Profile (NASDAQ:THMO)

ThermoGenesis Holdings, Inc develops, commercializes, and markets a range of automated technologies for chimeric antigen receptor (CAR)-T and other cell-based therapies. It markets a suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology, including its semi-automated, functionally closed CAR-TXpress platform, which streamlines the manufacturing process for the emerging CAR-T immunotherapy market.

Recommended Story: What is an investor looking for in an SEC filing?

Receive News & Ratings for ThermoGenesis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ThermoGenesis and related companies with's FREE daily email newsletter.